Plain-English translation of NCT06474520 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing , a supplement used in traditional Chinese medicine, to see if it can help treat inflammatory demyelinating diseases—conditions where the immune system attacks the protective coating around nerve fibers in the brain and spinal cord. Researchers believe this medication may work by changing gut bacteria and reducing inflammation. The study will enroll 250 people with conditions like multiple sclerosis, neuromyelitis optica spectrum disorder, and related diseases, plus healthy volunteers.
Inflammatory demyelinating diseases can cause serious disability because the immune system becomes overactive and damages nerves. Current treatments help some people, but researchers are looking for new options that might reduce inflammation and protect nerve cells better, particularly by working through the gut-brain connection.
You likely qualify if…
You likely don't qualify if…
If you join the patient group, you will receive your usual care plus either the medication (100 mg once daily for 12 weeks) or no additional treatment, depending on which group you're assigned to. Healthy volunteers will receive only the medication. You will need to have stable symptoms for at least 30 days before starting, and the study team will monitor your neurological condition throughout the 84-day treatment period to see if the medication improves your symptoms or reduces disability.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China